Triple-Negative Breast Cancer (TNBC) Recruiting Phase 3 Trials for Gemcitabine (DB00441)

Also known as: Triple-negative Breast Cancer

DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting3 IdentifierTitlePurposeDrugs
NCT03002103A Trial Evaluating the Efficacy and Safety of EndoTAGĀ®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast CancerTreatment